James River Group Holdings (JRVR) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
10 Aug, 2026Executive summary
Net income from continuing operations was $6.6M for Q2 2026, up 29% year-over-year; adjusted net operating income was $10.0M, down 14%.
Net income available to common shareholders rose 59% year-over-year to $4.4M for Q2 2026, with tangible common equity per share at $9.01.
Underwriting loss of $327K (combined ratio 100.2%) for Q2 2026, compared to a $2.1M profit (98.6%) in Q2 2025.
General and administrative expenses declined 9% in H1 2026 versus H1 2025, with significant reductions in Specialty Admitted (down 42%) and Corporate (down 12%) segments.
Sale of JRG Reinsurance Company Ltd. closed in April 2024, resulting in discontinued operations and strategic shift.
Financial highlights
Gross written premiums fell 29% year-over-year in Q2 2026 to $268.9M, driven by a 17% decline in Excess and Surplus Lines and a 76% drop in Specialty Admitted Insurance.
Net written premiums decreased 11% to $148.4M; net earned premiums dropped 9% to $139.0M in Q2 2026.
Net investment income was $20.3M for Q2 2026, nearly flat year-over-year.
Net realized and unrealized gains on investments were $1.0M in Q2 2026, mainly from bank loan and preferred stock portfolios.
Shareholders’ equity at June 30, 2026 was $522.6M, down 2.9% from December 2025.
Outlook and guidance
Management remains focused on underwriting discipline, risk selection, and profitable growth in core casualty and specialty divisions.
Premium retention increased to 55% from 47% year-over-year, reflecting a strategic shift away from fronting business in Specialty Admitted Insurance.
Competitive market conditions and selective underwriting expected to continue impacting premium volumes.
Expense management and capital allocation remain priorities.
Latest events from James River Group Holdings
- Q3 net loss of $40.7M driven by reserve charges, with E&S premium growth and strategic actions.JRVR
Q3 20248 Jul 2026 - Net loss of $10.9M driven by E&S reinsurance charge; E&S segment led growth amid lower premiums.JRVR
Q1 202614 May 2026 - 2025 marked a sharp turnaround to profitability, capital growth, and E&S-driven operational gains.JRVR
Q4 202527 Mar 2026 - Earnings rose on investment gains and strategic actions, but reserve and legal risks persist.JRVR
Q2 20242 Feb 2026 - Over 21 million common shares registered for resale by major investors, with no proceeds to the company.JRVR
Registration Filing16 Dec 2025 - Q4 2024 net loss of $92.7M; E&S premiums top $1B; 2025 outlook positive.JRVR
Q4 202416 Dec 2025 - Annual Meeting to vote on directors, auditor, compensation, and incentive plan amendments.JRVR
Proxy Filing2 Dec 2025 - Proxy covers director elections, auditor re-appointment, compensation, and plan amendments.JRVR
Proxy Filing2 Dec 2025 - Q1 net income dropped to $9M as E&S pricing rose and Specialty Admitted premiums declined.JRVR
Q1 202524 Nov 2025